Sneak peek: This cancer therapy could replace conventional radiation treatment

Dear Tech Digest Reader,

Today, I’m going to give you a sneak peek at the next TransTech Alert issue, which will be published tomorrow, Thursday, January 25. (You can still get it at our special discount until the end of tomorrow.)

As you know, cancer is still one of the greatest killers in the US and worldwide. According to the National Cancer Institute, 1.69 million Americans were newly diagnosed with cancer last year and over 600,000 died of it.

So it’s no surprise that this disease is one of the focal points of biotech research.

We do have several companies in our TransTech Alert portfolio that strive to revolutionize the cancer industry. But in the meantime, we’re still stuck with the traditional treatments: chemotherapy and radiation.

The well-known X-ray radiation treatment has major problems—first of all, its relatively unfocused targeting of tumors, which often leads to the growth of secondary tumors and the eradication of healthy cells surrounding the diseased tissue.

There’s also the not-so-small matter of the “exit dose.” An X-ray beam directed at a patient’s body will do this:

You see how the radiation enters the body (“entrance dose”) and moves all the way through it, exiting through the back—so there’s a lot of potential cell damage being done here.

There is an alternative, though, that’s already on the market. It’s a lot better at beaming its rays at the tumors and not at the surrounding tissue, thus causing much less damage than X-ray therapy.

Also, the “entrance dose” is much lower than with X-ray therapy... and there is no exit dose.

About 160,000 cancer patients worldwide have been treated with it so far.

You’ve never heard of it, you say? That’s no surprise, because the equipment is so gigantic that it takes up whole buildings to house it—with halls the size of tennis courts and concrete shields several yards thick.

Needless to say, the treatment, though proven effective, has been so costly that few insurance companies are willing to pay for it.

All that is about to change, thanks to the company I’m going to write about in this month’s TransTech Alert.

The company is not publicly traded at the moment, but I believe it will have an IPO (initial public offering) in the not-too-distant future. Its mission has been to shrink the massive equipment needed for this new therapy to a manageable size, so that hospitals can house it in their existing facilities without having to build an extra wing.

The company’s solution substantially lowers the cost and side effects of cancer therapy, and will make this particular treatment much more accessible to the general public.

I think until we have genetic ways to “switch off” cancer cells altogether (something a few of our portfolio companies are working on as we speak), this probably will be the therapy of choice for the near- to mid-term future.

If you’d like to hear more about this company (and the others in our portfolio), you can do so right now at a special price.

If you subscribe to TransTech Alert for one year, you’ll save 47% off the retail price. Two years saves you even more—a full 67%.

You'll get a thorough analysis of this new therapy and the company whose miniaturized technology spells major market success for the near future.

As part of your subscription, you will get:

You’ll also get my “transformational package” with all the information you’ll need to become an expert in anti-aging and life-extension science, including several videos, my book The Methuselah Effect, a special report detailing my five favorite biotech stocks, and more.

Click here to get all the details.

Just remember, this offer expires at midnight tomorrow, Thursday, January 25.

Sincerely,

Patrick Cox
Editor, Transformational Technology Alert

Copyright © 2018 Mauldin Economics.
All Rights Reserved Mauldin Economics, LLC | PO Box 192495 | Dallas, TX 75219
Click here to unsubscribe from promotional mailings.